Bio-Techne (TECH) said Tuesday that it has entered a distribution agreement with US Pharmacopeia, which will allow the life sciences company to sell US Pharmacopeia's monoclonal antibody and recombinant adeno-associated virus reference standards alongside its analytical platforms.
Financial terms of the deal were not disclosed.